Study of anti-free radical action of phytopreparations and their effectiveness on animals

With industrial technologies of animal husbandry, the state of the animal’s body is characterized by the presence of metabolic disorders considered as oxidative stress. Currently, in animal husbandry, characterized by stressful content in industrial complexes, the use of adaptogenic drugs is required; however, among their abundance, phytobiotics are the most effective in terms of optimizing metabolic processes. Phytobiotics are herbal preparations that are sources of biologically active substances. The work shows the results of studying anti-free radicals of phytobiotics (nettle, germinated wheat sprouts, clover, licorice, marsh cinquefoil and cranberry) in the POL-AOS model system and the results of the application of the developed method of antioxidant protection for high-yielding cows kept under stressful conditions under industrial dairy management. cattle breeding. The basic mechanism of action of phytopreparations based on nettle, germinated sprouts of wheat, clover, licorice, marsh cinquefoil and cranberry in the correction and prevention of biochemical disorders caused by stress is inhibition of free radical oxidation and activation of endogenous antioxidants

Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease—A Phase II Study

The efficacy and the safety of the administration of multipotent mesenchymal stromal cells (MMSCs) for acute graft-versus-host disease (aGVHD) prophylaxis following allogeneic hematopoietic cell transplantation (HSCT) were studied. This prospective clinical trial was based on the random patient allocation to the following two groups receiving (1) standard GVHD prophylaxis and (2) standard GVHD prophylaxis combined with MMSCs infusion. Bone marrow MMSCs from hematopoietic stem cell donors were cultured and administered to the recipients at doses of 0.9–1.3×106/kg when the blood counts indicated recovery. aGVHD of stage II–IV developed in 38.9% and 5.3% of patients in group 1 and group 2, respectively, (=0.002). There were no differences in the graft rejection rates, chronic GVHD development, or infectious complications. Overall mortality was 16.7% for patients in group 1 and 5.3% for patients in group 2. The efficacy and the safety of MMSC administration for aGVHD prophylaxis were demonstrated in this study